PPLPHARMA Piramal Pharma Q3 FY26 results (Oct–Dec 2025) and concall
Piramal Pharma reported a muted Q3 FY26, characterized by a slight revenue decline due to inventory destocking by a major customer and regulatory delays at the Digwal facility. Despite these headwinds, management highlighted a significant recovery in CDMO RFPs and order inflows since October 2025, driven by improved US biopharma funding. The strategic acquisition of Kenalog is expected to bolster the Complex Hospital Generics portfolio with high-margin, low-competition revenue.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue down 2.9%, net profit down 3500.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 2,242 | 2,204 | 2,754 | 1,934 | 2,044 −9% | 2,140 −3% |
| EBITDA | 342 | 338 | 561 | 107 | 159 −54% | 196 −42% |
| Net profit | 23 | 4 | 154 | -82 | -99 −530% | -136 −3500% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
